Tags: multiple sclerosis + treatment.with.MS

Sort by: Date / Title / URL

1. News - Neutralizing Antibodies Positivity Does Not Affect Clinical Outcome in Multiple Sclerosis Patients: Presented at ECTRIMS
   Neutralizing antibody (NAbs) positivity does not reduce the efficacy of interferon beta-1b (IFNbeta-1b) treatment, according to results of a substudy analysis of patients with a first event suggestive of multiple sclerosis (MS) in a multicentre, randomize
   17-10-2007 to betaseron, drugs, interferon, ms, multiple sclerosis, study, treatment by admin
2. ScienceDaily: Genes That Affect Responses Of Multiple Sclerosis Patients To Copaxone Identified
   In the past few years, it has been shown that many drugs are not equally effective for every patient, and this variability is due, at least in part, to genetic differences.
   11-10-2007 to copaxone, drug company, drugs, genetics, ms, multiple sclerosis, treatment by admin
3. globeandmail.com: New DNA vaccine holds hope for MS patients
   The vaccine incorporates the sequence of myelin basic protein (MBP), which is thought to be one of the targets of MS, and DNA is incorporated into the cells in the body, which then starts to make the protein.
   14-08-2007 to bht-3009, canada, genetics, ms, multiple sclerosis, research, treatment by admin
4. Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
   The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment.
   03-08-2007 to betaseron, drug company, drugs, interferon, ms, multiple sclerosis, newly diagnosed, study, treatment by admin
5. Taking a Risk for Science
   A revolutionary surgery that involves drilling a hole in the skull and injecting cells could repair some devastating effects of multiple sclerosis.
   01-07-2007 to clinical trial, multiple sclerosis, research, treatment, us by admin
6. Early Interferon Beta-1B (BetaseronR) In Multiple Sclerosis Patients Staves Off Disability
   "We have shown for the first time that immediate treatment after a first clinical demyelinating event suggestive of MS can reduce the early neurological damage, which may ultimately delay the development of the debilitating sequelae that characterize adv
   03-05-2007 to drugs, multiple sclerosis, newly diagnosed, relapsing remitting, research, rrms, study, treatment by admin
7. Newswise | Could Estriol Be the Elixir for MS?
   This month a UCLA researcher begins a widespread clinical trial of the female sex hormone estriol, produced during pregnancy, which she’s shown sharply reduces the symptoms of multiple sclerosis.
   01-04-2007 to clinical trial, drugs, hormones, multiple sclerosis, pregnancy, treatment, us by admin
8. Biogen, PDL drug passes clinical trial
   Patients given daclizumab every two weeks had a significantly reduced lesions at week 24 compared with those in the placebo group.
   13-03-2007 to clinical trial, daclizumab, drug company, drugs, interferon, multiple sclerosis, relapsing remitting, treatment by admin
9. Accentia Biopharmaceuticals Acquires Worldwide Exclusive License to Revimmune for All Autoimmune Diseases - PipelineReview.com | Business Intelligence Center
   In clinical studies for the lead indication of multiple sclerosis (MS), Revimmune improves function in most patients and stops progression in over 90% of cases refractory to standard therapies;
   05-03-2007 to drug company, drugs, immune, multiple sclerosis, revimmune, treatment by admin
10. BioMS Medical initiates follow-on open-label MAESTRO-02 Multiple Sclerosis trial of MBP8298
    BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has initiated MAESTRO-02, the open-label follow-on portion to its MAESTRO-01 pivotal phase II/III clinical trial of MBP8298
    05-03-2007 to drug company, drugs, mbp8298, multiple sclerosis, spms, treatment by admin
11. Peptimmune Online - CO - 14
    The new peptides have been found to be more effective than Copaxone® in in-vitro and in-vivo assays, as well as in animal disease models of MS.
    17-02-2007 to copaxone, drug company, drugs, eae, multiple sclerosis, research, treatment by admin
12. TERMS
    The TERMS (Tovaxin for Early Relapsing Multiple Sclerosis) study is testing Tovaxin, an autologous T-Cell vaccination in patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
    15-02-2007 to clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, tovaxin, treatment by admin
13. Merck Serono Has Initiated The Onward Study To Evaluate Oral Cladribine As Add-On Treatment For Multiple Sclerosis - PipelineReview.com | Business Intelligence Center
    Merck Serono announced today that it has begun the ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) Phase II study.
    07-02-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, rebif, research, treatment by admin
14. Disease > Parasite infection may benefit Multiple Sclerosis patients
    The first study examining the relationship between parasite infections and multiple sclerosis in humans suggests that such infections may affect the immune response in a way that alters the course of MS.
    19-01-2007 to multiple sclerosis, research, study, treatment by admin
15. Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
    Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
    17-01-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, research, rrms, treatment by admin

First / Previous / Next / Last / Page 1 of 8